Cowen Healthcare Investments
New York, New York, United StatesFounded 2012
Cowen Healthcare Investments (CHI) was a venture capital firm based in New York that invested fiduciary capital in innovative private healthcare companies across biopharma, diagnostics, and digital health. Founded in 2012, the firm was acquired by Blue Owl Capital in 2023 and became Blue Owl Healthcare Opportunities.
56% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (47% of deals). Average disclosed round size is $109.7M (across 38 rounds with reported amounts).
Portfolio
39
Fund Size
$555.6M
Top Stage
Series B
Last 12 Mo
0
Team
KR
Kevin Raidy
Managing Partner
TA
Tim Anderson
Managing Director
RS
Robert Sine
Partner/Head Trader
EP
Eric Pham
Senior Associate
SC
Sara Clarke
Associate
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
43 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Aro Biotherapeutics | Series B | $41.5M | Nov 2023 |
 MBrace | Series A | $85M | Nov 2023 |
 MapLight Therapeutics | Series C | $225M | Oct 2023 |
 MBrace Therapeutics | Series B | $85M | Jan 2023 |
 Nested Therapeutics | Series A | $90M | Oct 2022 |
| AAcelyrin, Inc | Series C | $300M | Sep 2022 |
| AAcelyrin | Series C | $300M | Sep 2022 |
 Aktis Oncology | Series A | $84M | Aug 2022 |
| DDelfi Diagnostics, Inc. | Series B | — | Jul 2022 |
 Delfi | Series B | — | Jul 2022 |
| EElectra Therapeutics | Series B | $84M | Feb 2022 |
| Delfi | Series B | $225M | Jan 2022 |
 Obsidian Therapeutics | Series B | $115M | Sep 2021 |
 Arch Oncology, Inc. | Series C | $105M | Apr 2021 |
 Evox Therapeutics | Series C | $95.4M | Feb 2021 |
 Delfi Diagnostics | Series A | $100M | Jan 2021 |
 Neuron23 | Series B | $113.5M | Dec 2020 |
 Autobahn Therapeutics | Series B | $76M | Jun 2020 |
 Nodthera | Series B | $55M | Jun 2020 |
 Keros Therapeutics | Series C | $56M | Mar 2020 |
 VectivBio | Unknown | $35M | Jan 2020 |
 Escient Pharmaceuticals | Series B | $77.5M | Jan 2020 |
 Oncorus | Series B | $79.5M | Jan 2019 |
 Oncorus, Inc | Series B | $79.5M | Jan 2019 |
 KSQ Therapeutics | Unknown | $80M | Sep 2018 |
Page 1 of 2
Top Co-Investors
OrbiMed14 shared
Samsara BioCapital10 shared
Surveyor Capital9 shared
Redmile Group7 shared
Foresite Capital7 shared
Northpond Ventures7 shared
Rock Springs Capital7 shared
Westlake Village BioPartners6 shared
Menlo Ventures6 shared
Cormorant Asset Management6 shared
Perceptive Advisors5 shared
Windham Capital Partners5 shared
RA Capital Management5 shared
venBio5 shared
Osage University Partners5 shared
MPM Capital4 shared
Illumina Ventures4 shared
T. Rowe Price4 shared
AV8 Ventures4 shared
Eli Lilly and Company4 shared
Last updated: 8 September 2026